Prochiral Alkyl-aminomethyl Ketones as Convenient Precursors for Efficient Synthesis of Chiral (2,3,5)- Tri-substitued Pyrrolidines *via* an Organo-Catalysed Tandem Reaction⁺

Yuming Song,*^a Ke Li, ^a Tao Shu, ^a Yamei Xie, ^a Yixin Zhang ^a and Jingping Qu^a.

⁺ State Key Laboratory of Fine Chemicals, School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian 116024, P. R. China

song-ym@dlut.edu.cn

Supporting information

Contents:

General

Materials

Determination of Diastereomeric and Enantiomeric Ratios

Crystal Data for compounds

General Procedures

Characterization of compounds

NMR spectra

General.

The ¹H and ¹³C NMR spectra were all recorded using a Bruker AV400 spectrometer (Ettlingen, Germany) operating at 400 MHz for ¹H and 100 MHz for ¹³C. The chemical shifts (δ) for ¹H and ¹³C are given in ppm relative to residual signals of the solvents (CDCl₃). Coupling constants are given in Hz. Carbon types were determined from DEPT ¹³C NMR experiments. The following abbreviations are used to indicate the multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; bs, broad signal. Purification of the reaction products was carried out by flash chromatography

(FC) on silica gel (200-300 mesh). High Resolution Mass spectra were obtained from the Dalian University of Technology. X-ray data were acquired on a Bruker APEX-2 diffractometer. All reactions were carried out in air and using distilled solvents, without any precautions to exclude moisture unless otherwise noted.

Materials.

Commercial grade reagents and solvents were used without further purification; otherwise, where necessary, they were purified as recommended.¹ Chiral and racemic amine catalysts 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine were prepared following the literature procedure.² Unsaturated aldehydes **1a-j** and were synthesized following the literature procedures.³⁻⁶ Aminoketone **2a-g** were prepared following the literature procedure.⁷⁻⁹

Determination of Diastereomeric Ratios.

The diastereomeric ratio was determined by ¹H NMR analysis of the crude reaction mixture.

Determination of Enantiomeric Purity.

Chiral HPLC analysis was performed on an Agilent 1100-series instrument.

Phenomenex Lux - Amylose 2 and Phenomenex Lux Cellulose 2 columns Daicel

Chiralpak AD-H and Daicel Chiralcel OD-H with hexane/i-PrOH as the eluent were used. HPLC traces for compounds **3** and corresponding enantiomers, were compared to *quasi* racemic samples.

- 4. Chuang, Ta-Hsien; Chen, Yu-Chi; Pola, Someshwar, Journal of Organic Chemistry, 2010.
- 5. Tachibana, Sanro; Ito, Kazutaka; Sumimoto, Masashi, Mokuzai Gakkaishi , 1989.
- 6. Andrea Togninelli, Harsukh Gevariya, Maddalena Alongi and Maurizio Botta, *Tetrahedron Letters*, 2007
- 7. Dunn, Nicole L.; Ha, Minji; Radosevich, Alexander T., *Journal of the American Chemical Society*, 2012.
- 8. Misra, Raj N.; Xiao, Hai-yun; Kim, Kyoung S., Journal of Medicinal Chemistry, 2004.

^{1.} W. L. F. Armarengo, D. D. Perrin, In *Purification of Laboratory Chemicals*, 4th ed.; Butterworth Heinemann: Oxford, 1996.

^{2.} Marigo, Mauro; Wabnitz, Tobias C.; Fielenbach, Doris; Jorgensen, Karl Anker, *Angewandte Chemie - International Edition*, 2005.

^{3.} Garayalde, David; Gomez-Bengoa, Enrique; Huang, Xiaogen; Goeke, Andreas; Nevado, Cristina, *Journal of the American Chemical Society*, 2010.

9. Mastalerz, Harold; Gavai, Ashvinikumar V., Canadian Journal of Chemistry, 2006.

Crystal Data for compound

Table S1. Cry	ystallographic data for 3aa

	3aa
Formula	C ₁₉ H ₂₀ NO ₄ S
Formula weight	358.42
Crystal dimensions (mm ³)	$0.31 \times 0.27 \times 0.23$
Crystal system	Orthorhombic
Space group	P2(1)2(1)2(1)
a (Å)	7.3097(11)
b (Å)	10.0954(15)
c (Å)	24.274(4)
α (°)	90.00
β (°)	90.00
γ (°)	90.00
Volume (Å ³)	1791.2(5)
Ζ	4
<i>T</i> (K)	298(2)
D_{calcd} (g cm ⁻³)	1.329
$\mu (\mathrm{mm}^{-1})$	0.204
F (000)	756
No. of rflns. collected	8108
No. of indep. rflns. $/R_{int}$	3156 / 0.0187
No. of obsd. rflns. $[I_0 > 2\sigma(I_0)]$	2972
Data / restraints / parameters	3156 / 0 / 226
$R_1 / wR_2 [I_0 > 2\sigma(I_0)]^a$	0.0323 / 0.0890
R_1 / wR_2 (all data) ^a	0.0353 / 0.0890
GOF (on F^2) ^a	1.041
Largest diff. peak and hole (e Å-3)	0.228/-0.245



Table S2. Selected bond distances (Å) and bond angles (°) for 3aa

Distances (Å)			
N1C1	1.458(3)	O4–C5	1.203(2)
N1-C4	1.475(2)	C1–C2	1.507(3)
N1-S1	1.6186(16)	C2–C3	1.536(3)
S101	1.4307(16)	С3-С7	1.508(3)
S1–O2	1.4378(15)	С3–С4	1.568(3)
S1C13	1.753(2)	C4–C5	1.530(3)
O3–C1	1.422(3)	С5-С6	1.483(3)
Angles (°)			
O1-S1-O2	119.87(11)	N1-C1-C2	100.82(17)
O1-S1-N1	107.03(9)	C1–C2–C3	102.80(16)
O2-S1-N1	105.24(9)	С7-С3-С2	117.07(16)
O1-S1-C13	108.66(10)	С7-С3-С4	116.60(16)
O2-S1-C13	106.81(9)	C2-C3-C4	102.49(15)
N1-S1-C13	108.82(9)	N1-C4-C5	110.99(15)
C1-N1-C4	113.19(15)	N1-C4-C3	101.78(14)
C1-N1-S1	122.78(14)	C5–C4–C3	112.53(15)
C4-N1-S1	121.33(12)	O4–C5–C6	122.63(19)
O3-C1-N1	109.02(18)	O4–C5–C4	120.25(18)
O3-C1-C2	112.78(19)	C6-C5-C4	117.11(16)

	3 j ₂
Formula	C ₁₉ H _{22.5} NO _{4.5} S
Formula weight	368.94
Crystal dimensions (mm ³)	$0.29 \times 0.14 \times 0.15$
Crystal system	Orthorhombic
Space group	P2(1)2(1)2(1)
a (Å)	10.156(3)
b (Å)	17.874(5)
c (Å)	20.771(6)
α (°)	90.00
β (°)	90.00
γ (°)	90.00
Volume (Å ³)	3770.6(18)
Ζ	8
<i>T</i> (K)	298(2)
$D_{\text{calcd}} (\text{g cm}^{-3})$	1.300
μ (mm ⁻¹)	0.197
F (000)	1564
No. of rflns. collected	21290
No. of indep. rflns. $/R_{int}$	6643 / 0.0705
No. of obsd. rflns. $[I_0 > 2\sigma(I_0)]$	4203
Data / restraints / parameters	6643 / 0 / 451
$R_1 / wR_2 [I_0 > 2\sigma(I_0)]^{a}$	0.0585 / 0.1402
R_1 / wR_2 (all data) ^a	0.1043 / 0.1594
GOF (on F^2) ^a	1.006
Largest diff. peak and hole (e Å-3)	0.194/ -0.384

Table S3. Crystallographic data for 3aa'



Table S4. Selected bond distance	es (Å) and l	bond angles	(°) for 3aa'
----------------------------------	--------------	-------------	---------------------

Distances (Å)			
S1O1	1.427(3)	O4–C1	1.412(4)
S1–O2	1.428(3)	N1-C1	1.476(5)
S1-N1	1.612(2)	N1-C4	1.481(4)
S1-C13	1.744(5)	С3–С7	1.515(6)
O3–C5	1.207(5)		
Angles (°)			
O1–S1–O2	119.4(2)	N1-C1-C2	102.37(18)
O1-S1-N1	107.75(17)	C1–C2–C3	105.2(4)
O2-S1-N1	105.76(16)	С7–С3–С2	115.9(4)
O1-S1-C13	106.9(2)	С7-С3-С4	114.0(3)
O2-S1-C13	109.6(2)	C2–C3–C4	103.0(3)
N1-S1-C13	106.82(19)	N1-C4-C5	115.2(3)
C1-N1-C4	112.74(17)	N1-C4-C3	102.8(3)
C1-N1-S1	121.69(8)	C5–C4–C3	108.8(3)
C4-N1-S1	121.4(2)	O3–C5–C6	121.7(4)
O4C1N1	110.37(17)	O3-C5-C4	118.5(4)
O4–C1–C2	110.6(3)	C6-C5-C4	119.7(4)

General Procedure

The preparation racemic products

(R,S)-2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.02 mmol, 13 mg, 10 mol%) was dissolved in 1 mL of CH₂Cl₂ and benzoic acid (0.04 mmol, 5 mg, 20 mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar . The resulting solution was stirred at room temperature for 20 minutes, then α , β -unsaturated aldehyde (0.2 mmol) and aminoketone (0.25mmol) were added. The vial was stirring continued at room temperature for 48 hours. The crude mixture was flushed through a short plug of silica.

General Procedure for chiral pyrrolidines synthesis

(R)-2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.08 mmol, 26 mg, 20 mol%) was dissolved in 2.0 mL of CH_2Cl_2 and 4-Bromobenzene carboxylic acid (0.08 mmol, 16 mg, 20 mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar . The resulting solution was stirred at room temperature for 20 minutes, then α,β -unsaturated aldehyde (0.4 mmol) and aminoketone (0.5 mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in *vacuo* and the diastereomeric ratio (dr) was determined by ¹H NMR analysis of the crude mixture. The desired compound was isolated by flash column chromatography.

1-((2S,3S)-5-hydroxy-3-phenyl-1-tosylpyrrolidin-2-yl)ethanone (3aa) and 1-((2S,3R,5S) -5-hydroxy -3-phenyl -1-tosyl pyrrolidin -2-yl) ethanone (3aa')



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.04mmol., 13 mg, 10 mol%) was dissolved in 2.0 mL of CH₂Cl₂ and benzoic acid (0.08mmol., 10 mg, 20 mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 minutes, then cinnamaldehyde (0.4mmol) and 4-methyl-N-(2-oxopropyl)benzene-sulfonamide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in *vacuo*. After flash column chromatography (hexane/ethyl acetate =4/1) 2,3-*cis* isomer **3aa**, (71.9 mg, 49 % yield, Mp. 135-136 °C, dr=5:4 and 99% ee (Fcester)) and 2,3-*trans* isomer **3aa'** (56.0 mg, 40% yield, Mp. 141-142 °C, 99% ee) were obtained as amorphous solids. The dr and ee of **3aa** were determined by ¹H NMR and HPLC analysis respectively. (Daicel Chiralcel OD-H column: hexane/*i*-PrOH 80:20, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{major} = 24.9$ min; $\tau_{minor} = 14.7$ min). ¹H NMR

(400 MHz, CDCl₃): 7.73-7.77 (t, J = 8.4 Hz, 2H), 7.28-7.32 (m, 5H), 7.14-7.16 (d, J = 7.4 Hz, 2H), 5.68-5.69, 5.74-5.76 (d, 1H), 4.68-4.70, 4.86-4.88 (d, 1H), 4.17-4.21, 3.51-3.58 (m, 1H), 3.90-3.92, 3.66 (m, 1H), 2.53,2.64 (m, 1H), 2.43 (d, 3H), 2.05-2.09 (m, 1H), 1.59-1.66 (s, 1H), 1.43 (s, 2H). ¹³C NMR (400 MHz, CDCl₃): 208.3, 205.9, 144.0, 136.7, 136.6, 134.8, 134.7, 129.8, 129.6, 129.0, 128.9, 128.2, 128.1, 128.0, 127.9, 127.5, 127.4, 84.7, 83.1, 69.9, 69.5, 58.5, 47.2, 45.2, 38.0, 36.5, 29.8, 29.7, 21.6, 18.4. HRMS: ESI ORBITRAP (+) m/z: calculated for C₁₉H₂₁NO₄S 359.1191, found [M+Na]⁺ 382.1079.



The ee of **3aa'** was determined by HPLC analysis on a Daicel Chiralcel OD-H column: hexane/*i*-PrOH 80:20, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{minor} = 12.0$ min $\tau_{major} = 14.4$ min. ¹H NMR (400 MHz, CDCl₃) : 7.73 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 7.23 (td, J = 5.5, 2.7 Hz, 2H), 6.97 (dd, J = 7.4, 2.0 Hz, 2H), 5.61 (d, J = 5.4 Hz, 1H), 3.98 (d, J = 8.9 Hz, 1H), 3.66 (ddd, J = 11.3, 8.8, 6.7 Hz, 1H), 3.35 (s, 1H), 2.47 (s, 3H), 2.37 (s, 3H), 2.25 (dd, J = 13.2, 6.7 Hz, 1H), 1.83 (ddd, J = 13.1, 11.4, 5.6 Hz, 1H). ¹³C NMR (400 MHz, CDCl₃): 206.9, 144.5, 138.0, 134.8, 130.1, 128.9, 127.7, 127.3, 127.2, 84.8, 77.4, 77.1, 76.7, 74.4, 46.6, 41.4, 25.5, 21.6. HRMS ESI ORBITRAP (+) m/z: calculated for C₁₉H₂₁NO₄S 359.1191, found [M+Na]⁺ 382.1079.



1-((2\$,3\$,5R)-5-hydroxy-3-phenyl-1-tosylpyrrolidin-2-yl)-2,2-dimethylpropan-1one (3af)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.08mmol., 26mg, 20mol%) was dissolved in 2.0 mL of CH₂Cl₂ and 4-bromobenzene carboxylic acid (0.08mmol., 16mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar . The resulting solution was stirred at room temperature for 20 minutes, then cinnamicaldehyde (0.4mmol) and N-(3,3-dimethyl-2-oxidanylidene-but yl)-4-methyl-benzenesulfonamide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =4/1) 3af was obtained as amorphous solid (120.3mg, 75% yield, dr=8:1 and 98% ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralcel OD-H column: hexane/*i*-PrOH 70:30, flow rate 0.60 mL/min, $\lambda = 254.0$ nm: $\tau_{maior} = 14.2$ min, $\tau_{minor} =$ 12.0 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₂₂H₂₇NO₄S 401.1661, found 424.1562 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 7.76 (d, J = 8.3 Hz, 2H), 7.32 -7.27 (m, 4H), 7.08 (dd, J = 7.7, 1.5 Hz, 2H), 5.84 (s, 1H), 5.08 (d, J = 4.5 Hz, 1H), 4.23 (s, 1H), 3.30 (td, J = 7.7, 4.5 Hz, 1H), 2.44 (s, 3H), 2.35 (ddd, J = 13.6, 8.1, 2.1 Hz, 1H), 2.27 – 2.18 (m, 1H), 1.02 (s, 9H). ¹³C NMR (400 MHz, CDCl₃): 216.3, 143.8, 141.6, 137.1, 129.6, 129.1, 127.6, 127.4, 126.9, 85.2, 68.2, 49.3, 45.6, 43.6, 26.5, 21.6. Mp (°C): 178-179.





4-((2S,3S,5R)-5-hydroxy-2-pivaloyl-1-tosylpyrrolidin-3-yl)benzonitrile (3bf)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.08mmol., 26mg, 20mol%) was dissolved in 2.0 mL of CH₂Cl₂ and 4-bromobenzene carboxylic acid (0.08mmol, 16mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 minutes. then 4-cyanocinnamicaldehyde (0.4 mmol)and N-(3,3-dimethyl-2oxidanylidene-butyl)-4-methyl-benzenesulfonamide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =4/1) **3bf** was obtained an amorphous solid (135.2 mg, 79 % yield, dr = 15:1 and 99% ee. ¹H NMR (400 MHz, CDCl₃): 7.74 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.1 Hz,8.4 Hz, 2H), 5.87-5.91 (m, 1H), 5.07 (d, J = 4.0 Hz, 1H), 4.28 (d, J = 9.6 Hz, 1H), 3.32-3.37 (m, 1H), 2.45 (s, 3H), 2.38-2.42 (m, 1H), 2.23-2.30 (m, 1H), 1.03 (s, 9H). ¹³C NMR (400 MHz, CDCl₃): 215.3, 147.2, 144.1, 136.8, 133.0, 129.6, 127.7, 127.4, 118.3, 111.6, 85.1, 67.6, 48.9, 45.0, 43.7, 26.4, 21.6. Daicel Chiralcel OD-H column: hexane/*i*-PrOH 80:20, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{maior} = 20.5$ min, τ_{mminor} = 24.4 min. HRMS ESI ORBITRAP (+) m/z: calculated for $C_{23}H_{26}N_2O_4S$ 426.1613, found [M+Na]+ 449.1507. Mp. 147-148 °C.



1-((2S,3S,5R)-5-hydroxy-3-(4-nitrophenyl)-1-tosylpyrrolidin-2-yl)-2,2dimethylpropan-1-one (3cf)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.08mmol., 26mg, 20mol%) was dissolved in 2.0 mL of CH₂Cl₂ and 4-bromobenzene carboxylic acid (0.08mmol, 16mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 minutes, then 4-nitrocinnamicaldehyde (0.4 mmol)and N-(3,3-dimethyl-2oxidanylidene-butyl)-4-methyl-benzenesulfonamide(0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =4/1) **3cf** was obtained as amorphous solid (144.0 mg, 81% yield, dr=15:1 and >99% ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralcel OD-H column: hexane/*i*-PrOH 80:20, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{maior} = 19.5$ min, τ_{minor} = 27.9 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₂₃H₂₈N₂O₆S 446.1512, found 469.1403 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 7.74 (d, J = 8.0Hz, 2H), 7.41 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 5.83-5.85 (m, 1H), 5.02 (d, J = 4.4 Hz, 1H), 4.23 (s, 1H), 3.24-3.29 (m, 1H), 2.44 (s, 3H), 2.31-2.37 (m, 1H), 2.17-2.31 (m, 1H), 1.04 (s, 9H). ¹³C NMR (400 MHz, CDCl₃): 215.9, 143.9, 140.8, 137.0, 132.3, 129.6, 128.5, 127.4, 85.1, 68.0, 48.7, 45.3, 43.7, 26.5, 21.6. Mp (°C): 166-167.





1-((2S,3S,5R)-3-(4-bromophenyl)-5-hydroxy-1-tosylpyrrolidin-2-yl)-2,2dimethylpropan-1-one (3df)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.08mmol., 26mg, 20mol%) was dissolved in 2.0 mL of CH₂Cl₂ and 4-bromobenzene carboxylic acid (0.08mmol., 16mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 minutes. then 4-bromocinnamicaldehyde (0.4mmol) and N-(3,3-dimethyl-2oxidanylidene-butyl)-4-methyl-benzenesulfonamide(0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =4/1) **3df** was obtained as amorphous solid (121.7 mg, 64% yield, dr=6:1 and 98% ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralcel OD-H column: hexane/*i*-PrOH 80:20, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{major} = 14.2$ min, $\tau_{minor} =$ 10.9 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₂₂H₂₆BrNO₄S 479.0766, found 502.0660 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 8.17 (d, J = 8.8 Hz, 2H), 7.75 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 5.88-5.93 (m, 1H), 5.08 (d, J = 3.6 Hz, 1H), 4.29 (d, J = 9.6 Hz, 1H), 3.39-3.43 (m, 1H), 2.45 (s, 3H), 2.38-2.42 (m, 1H), 2.25-2.32 (m, 1H), 1.04 (s, 9H). ¹³C NMR (400 MHz, CDCl₃): 215.3, 149.3, 147.3, 144.1, 136.9, 129.6, 127.8, 127.4, 124.4, 85.1, 67.6, 48.7, 45.1,





1-((2S,3S,5R)-5-hydroxy-3-(3-nitrophenyl)-1-tosylpyrrolidin-2-yl)-2,2dimethylpropan-1-one (3ef)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.08mmol., 26mg, 20mol%) was dissolved in 2.0 mL of CH₂Cl₂ and 4-bromobenzene carboxylic acid (0.08mmol., 16mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 3-nitrocinnamicaldehyde and minutes. then (0.4 mmol)N-(3,3-dimethyl-2oxidanylidene-butyl)-4-methyl-benzenesulfonamide(0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =4/1) **3ef** was obtained as amorphous solid (149.7 mg, 84% yield, dr=4:1 and 97% ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 80:20, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{maior} = 18.5$ min, $\tau_{minor} =$ 27.4 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₂₂H₂₆N₂O₆S₆ 446.1512, found 469.1407 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 8.12-8.15 (m, 1H), 7.89 (s, 1H), 7.75 (d, J = 8.0 Hz, 2H), 7.52-7.53 (m, 2H), 7.31 (d, J = 8.4 Hz, 1H), 5.88 (d, J= 4.0 Hz, 1H), 5.06 (d, J = 4.0 Hz, 1H), 4.27 (s, 1H), 3.41-3.47 (m, 1H), 2.45 (s, 3H),2.38-2.42 (m, 1H), 2.21-2.70 (m, 1H), 1.06 (s, 9H). ¹³C NMR (400 MHz, CDCl₃): 215.3, 148.5, 144.2, 143.8, 136.7, 132.9, 130.4, 129.7, 127.3, 122.7, 121.8, 85.0, 67.7, 48.6, 45.0, 43.8, 26.5, 21.6. Mp (°C): 52-53.





(2R,4S,5S)-4-(4-methoxyphenyl)-5-pivaloyl-1-tosylpyrrolidin-2-ferrocenyl-acetate (3ff)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.08mmol., 26mg, 20mol%) was dissolved in 2.0 mL of CH₂Cl₂ and 4-bromobenzene carboxylic acid (0.08mmol., 16mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar . The resulting solution was stirred at room temperature for 20 minutes, then 4-methoxyphenylacrylaldehyde (0.4mmol) and N-(3,3-dimethyl-2-oxidanylidene-butyl)-4-methyl-benzenesulfonamid e (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in *vacuo*. After flash column chromatography (hexane/ethyl acetate =4/1) **3ff** was obtained as amorphous solid (70.9 mg, 41% yield, dr=8:1 and 99% ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 80:20, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{major} = 10.4$ min, $\tau_{minor} = 17.2$ min. HRMS ESI ORBITRAP (+) m/z: calculated for C₃₄H₃₇FeNO₆S 643.1691,

found 666.1578 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 7.80 (d, J = 8.3 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 6.72 (d, J = 3.9 Hz, 1H), 5.05 (d, J = 8.0 Hz, 1H), 4.88 (dt, J = 2.5, 1.3 Hz, 1H), 4.76 (dt, J = 2.5, 1.3 Hz, 1H), 4.44 – 4.37 (m, 2H), 4.22 (s, 5H), 3.80 (s, 3H), 3.43 (dt, J = 10.6, 7.3 Hz, 1H), 2.40 (s, 3H), 0.97 (s, 9H). ¹³C NMR (400 MHz, CDCl₃): 213.8, 170.8, 159.2, 143.9, 136.6, 129.6, 128.6, 127.6, 114.5, 84.7, 71.5, 70.7, 69.9, 68.1, 60.9, 56.3, 55.3, 48.9, 43.8, 43.0, 27.0, 21.6. Mp (°C): 112-113.



(2R,4S,5S)-4-(4-ethyl-3,5-dimethoxyphenyl)-5-pivaloyl-1-tosylpyrrolidin-2-ferrocenyl acetate (3gf)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.08mmol, 26mg, 20mol%) was dissolved in 2.0 mL of CH₂Cl₂ and 4-bromobenzene carboxylic acid (0.08mmol., 16mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 minutes, then 3,4,5-trimethoxyphenylacrylaldehyde (0.4mmol) and N-(3,3-dimethyl-2-oxidanylidene-butyl)-4-methyl-benzenesulfonamide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =4/1) **3gf** was obtained as amorphous solid (137.7 mg, 70% yield, dr=7:1 and 99% ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralcel OD-H column: hexane/*i*-PrOH 80:20, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{maior} = 15.7$ min, $\tau_{minor} =$ 35.2 min. HRMS ESI ORBITRAP (+) m/z: calculated forC₃₆H₄₁FeNO₈S 703.1902, found 726.1791 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 7.82 (d, J = 8.3 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 6.78 (d, J = 3.0 Hz, 1H), 6.41 (s, 2H), 5.13 (d, J = 7.1 Hz, 1H),4.87 (s, 1H), 4.74 (s, 1H), 4.45 - 4.36 (m, 2H), 4.21 (s, 5H), 3.83 (s, 9H), 3.38 (d, J =9.2 Hz, 1H), 2.39 (s, 3H), 1.01 (s, 9H). ¹³C NMR (400 MHz, CDCl₃): 213.42, 170.71, 153.64, 143.89, 136.65, 134.54, 129.46, 127.62, 104.29, 84.91, 69.88, 67.62, 60.89, 56.22, 49.52, 43.76, 26.76, 21.51. Mp (°C): 128-129.





1-((2S,3S,5R)-3-(furan-2-yl)-5-hydroxy-1-tosylpyrrolidin-2-yl)-2,2dimethylpropan-1-one (3hf)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.08mmol., 26mg, 20mol%) was dissolved in 2.0 mL of CH₂Cl₂ and 4-bromobenzene carboxylic acid (0.08mmol., 16mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar . The resulting solution was stirred at room temperature for 20 2-furylcinnamicaldehyde minutes. then (0.4 mmol)and N-(3,3-dimethyl-2oxidanylidene-butyl)-4-methyl-benzenesulfonamide(0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =4/1) **3hf** was obtained as amorphous solid (66.8 mg, 43% yield, dr=11:1 and 94% ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralcel OD-H column: hexane/*i*-PrOH 80:20, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{major} = 10.2$ min, $\tau_{minor} =$ 11.3 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₂₀H₂₅NO₅S 391.1453, found 414.1348 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 7.67 (d, J = 8.0 Hz, 2H),

7.24 (d, J = 7.2 Hz, 3H), 6.21(m, 1H), 5.99 (d, J = 3.2 Hz, 1H), 5.69-5.70 (m, 1H), 5.12 (d, J = 3.6 Hz, 1H), 3.93 (s, 1H), 3.37-3.41 (m, 1H), 2.37-2.43 (m, 4H), 2.18-2.24 (m, 1H), 1.15 (s, 9H). ¹³C NMR (400 MHz, CDCl₃): 153.0, 143.6, 142.1, 136.8, 129.5, 127.3, 110.4, 106.5, 84.7, 65.6, 44.0, 42.0, 40.3, 26.4, 21.5. Mp (°C): 55-56.



1-((28,38,5R)-5-hydroxy-3-(naphthalen-1-yl)-1-tosylpyrrolidin-2-yl)-2,2-

dimethylpropan-1-one (3if)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.08mmol., 26mg, 20mol%) was dissolved in 2.0 mL of CH₂Cl₂ and 4-bromobenzene carboxylic acid (0.08mmol., 16mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 minutes, then 1-naphthalenencinnamicaldehyde (0.4mmol) and N-(3,3-dimethyl-2oxidanylidene-butyl)-4-methyl-benzenesulfonamide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =4/1) **3if** was obtained as amorphous solid (80.1 mg, 44% yield, dr=7:1 and 87% ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 80:20, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{maior} = 7.9$ min, $\tau_{minor} =$ 14.4 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₂₆H₂₉NO₄S 451.1817, found 474.1934 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 7.76-7.89 (m, 5H), 7.48-7.50 (m, 2H), 7.43 (d, J = 5.2 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 5.86 (s, 1H), 5.48 (d, J =4.4 Hz, 1H), 4.38 (s, 1H), 4.01 (s, 1H), 2.50-2.56 (m, 1H), 2.46 (s, 3H), 2.33 (s, 1H), 0.94 (s, 9H). ¹³C NMR (400 MHz, CDCl₃): 216.6, 143.8, 137.3, 134.1, 130.8, 130.1, 129.6, 129.4, 128.20, 127.8, 127.6, 126.6, 125.9, 125.8, 122.3, 85.1, 67.0, 45.4, 43.7, 40.3, 26.9, 26.3, 21.6. Mp (°C): 160-162.





1-((2S,3S,5R)-3-(anthracen-9-yl)-5-hydroxy-1-tosylpyrrolidin-2-yl)ethanone (3ja)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.04mmol , 13mg, 10 mol%) was dissolved in 2.0 mL of CH₂Cl₂ and benzoic acid (0.08mmol., 10mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 minutes, then 3-(anthracen-9-yl)acrylaldehyde (0.4mmol) and 4-methyl-N-(2-oxopropyl)benzene-su Ifonamide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =6/1) **3ja** was obtained as amorphous solid (175.9mg, 96% yield, dr=25:1 and >99%ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 80:20, flow rate 0.60 mL/min, λ = 254.0 nm: τ_{major} = 12.2min, τ_{minor} = 18.1 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₂₇H₂₅NO₄S 459.1504, found 482.1387 [M+Na]⁺. ¹H NMR (400 MHz, $CDCl_3$): 8.42 (s, 1H), 8.01 (d, J = 8.4 Hz, 2H), 7.91 (d, J = 8.4 Hz, 2H), 7.73 (s, 1H), 7.26-7.48 (m, 7H), 5.95 (d, J = 8.4 Hz, 1H), 5.12 (m, 1H), 5.07 (d, J = 8.4 Hz, 1H), 3.68 (s, 1H), 2.79-2.87 (m, 1H), 2.57 (s, 3H), 2.39 (dd, J = 13.6, 8.4 Hz, 1H), 2.21 (s, 3H). ¹³C NMR (400 MHz, CDCl₃): 207.9, 144.4, 136.4, 131.8, 130.3, 130.2, 129.9, 128.9, 128.7, 127.4, 126.5, 124.8, 123.0, 85.1, 72.4, 41.5, 40.7, 26.3, 21.7. Mp. (°C):





1-((2S,3S,5R)-3-(anthracen-9-yl)-5-hydroxy-1-tosylpyrrolidin-2-yl)propan-1-one (3jd)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.04mmol, 13mg, 10mol%) was dissolved in 2.0 mL of CH₂Cl₂ and benzoic acid (0.08mmol, 10mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 minutes, then 3-(anthracen-9-yl)acrylaldehyde (0.4mmol) and 4-methyl-N-(2-oxobutyl)benzenesulfonamide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in *vacuo*. After flash column chromatography (hexane/ethyl acetate =6/1) **3jd** was obtained as amorphous solid 181.1mg, (96% yield, dr=10:1 and 97%) ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 80:20, flow rate 0.60 mL/min, λ = 254.0 nm: τ_{major} = 11.0 min, τ_{minor} = 21.3 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₂₈H₂₇NO₄S 473.1661, found 496.1546 [M+Na]⁺. ¹H NMR (400 MHz, $CDCl_3$): 8.43 (s, 1H), 8.03 (d, J = 8.5 Hz, 2H), 7.90 (d, J = 7.9 Hz, 2H), 7.73 (d, J =7.8 Hz, 1H), 7.44 (t, J = 7.3 Hz, 4H), 7.30 (d, J = 7.7 Hz, 3H), 5.95 (d, J = 4.5 Hz, 1H), 5.16 (d, J = 8.2 Hz, 1H), 5.12 – 5.00 (m, 1H), 3.84 (d, J = 4.5 Hz, 1H), 2.90 – 2.78 (m, 1H), 2.56 (s, 3H), 2.38 (dd, J = 13.0, 7.9 Hz, 2H), 2.26 (dd, J = 18.6, 7.4 Hz, 1H), 0.92 (t, J = 7.2 Hz, 3H). ¹³C NMR (400 MHz, CDCl₃): 210.77, 144.46, 143.66, 137.51, 136.12, 131.74, 129.94, 129.72, 129.03, 128.35, 127.54, 127.36, 124.98, 71.52, 70.34, 42.40, 41.07, 34.48, 21.73, 7.12. Mp (°C): 163-164.





1-((2S,3S,5R)-3-(anthracen-9-yl)-5-hydroxy-1-tosylpyrrolidin-2-yl)-2methylpropan-1-one (3je)



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.04mmol., 13mg, 10mol%) was dissolved in 2.0 mL of CH₂Cl₂ and benzoic acid (0.08mmol., 10mg, 20mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 minutes, then 3-(anthracen-9-yl)acrylaldehyde (0.4mmol) and 4-methyl-N-(3-methyl-2-oxobutyl)benzenesulfonamide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =6/1) **3**je was obtained as amorphous solid (178.9mg, 92% yield, dr=13:1 and 96% ee). The dr was determined by ¹H NMR and the ee was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/i-PrOH 80:20, flow rate 0.60 mL/min, $\lambda = 254.0$ nm: $\tau_{major} = 11.7$ min, $\tau_{minor} = 31.2$ min. HRMS ESI ORBITRAP (+) m/z: calculated for C₂₈H₂₇NO₄S 487.1817, found 510.1703 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 8.44 (s, 1H), 8.04 (d, *J* = 8.4 Hz, 3H), 7.88 (d, *J* = 8.4 Hz, 3H), 7.40-7.49 (m, 6H), 6.00 (dd, J = 6.4, 4.8 Hz, 1H), 5.43 (d, J = 7.6 Hz, 1H), 4.96-5.03 (m, 1H), 4.18 (d, J = 6.8 Hz, 1H), 2.83-2.91 (m, 1H), 2.52 (s, 3H), 2.43 (dd, J = 13.2, 8.4Hz, 1H), 2.22-2.29 (m, 1H), 0.88 (d, J = 6.8 Hz, 3H), 0.64 (d, J = 6.8 Hz, 3H). ¹³C NMR (400 MHz, CDCl₃): 215.4, 144.1, 137.3, 131.8, 129.9, 129.8, 128.8, 127.4,

DAD1 A, Sig=254 4 Ref=550,100 (LK405\15112008.D) Area: 52519.A mAU. 449 1000 800 81.08 rea. 525T.2 600 -400 . 200 -0 10 15 20 25 30 35 min Peak RetTime Type Width Height Area Area [min] [min] [mAU*s] [mAU] # 융 ---- |----- |---- |----- |------ |-----____] ----| 11.449 MM T 0.7412 5.25194e4 1180.91882 49.9725 1 2 30.188 MM T 1.8139 5.25772e4 483.08755 50.0275 DAD1 A, Sig=254,4 Ref=550,100 (LK405\15112010.D) 172531 mAU · 1750 -1500 1250 -1000 -750 500 e8.3148.19 250 220 0 20 10 15 25 30 35 min Peak RetTime Type Width Height Area Area [min] [min] [mAU*s] [mAU] 웅 # ----|-----|----|-----|-----| 1 11.670 MM T 1.4086 1.72537e5 2041.40356 98.2081 35.51200

127.2, 126.6, 125.0, 123.6, 84.9, 70.1, 43.1, 42.1, 39.6, 21.7, 18.1, 16.8. Mp (°C): 148-149.

(2S,4S,5R)-5-acetyl-4-(4-nitrophenyl)-1-tosylpyrrolidin-2-ferrocenyl acetate (3ca) and (2R,4S,5S)-5-acetyl-4-(4-nitrophenyl)-1-tosylpyrrolidin-2-ferrocenyl acetate (3ca')

1.4775 3148.18896

1.7919

2

31.220 MM T



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.04mmol., 13 mg, 10 mol%) was dissolved in 2.0 mL of CH₂Cl₂ and benzoic acid (0.08mmol., 10 mg, 20 mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar. The resulting solution was stirred at room temperature for 20 minutes, then 4nitrocinnamicaldehyde (0.4mmol) and 4-methyl-N-(2-oxopropyl)benzene-sulfonamide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in *vacuo*. After flash column chromatography (hexane/ethyl acetate =4/1) reaction product was obtained as amorphous solid (158.7mg, 98% yield, dr=10:7, 3ca >99% ee (Fc ester), 3ca' >99% ee (Fc ester)). The dr was determined by ¹H NMR and the ee of **3ca** was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 70:30, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{major} = 23.0$ min, $\tau_{minor} =$ 52.0 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₃₀H₂₈FeN₂O₇S 616.0967, found 639.0851 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 8.19 (d, J = 8.4 Hz, 2H), 7.83 (d, J = 8.2 Hz, 2H), 7.36 (dd, J = 14.9, 8.4 Hz, 4H), 6.81 (d, J = 4.6 Hz, 1H), 4.87 -4.75 (m, 2H), 4.63 (s, 1H), 4.44 (d, J = 9.8 Hz, 2H), 4.25 (s, 5H), 4.20 - 4.06 (m, 1H),2.96 - 2.85 (m, 1H), 2.46 (s, 3H), 2.26 (dd, J = 13.1, 5.6 Hz, 1H), 1.68 (s, 3H). ¹³C NMR (400 MHz, CDCl₃): 205.45, 170.74, 147.68, 144.44, 141.91, 136.25, 129.76, 127.99, 124.03, 84.01, 77.39, 76.75, 71.60, 70.36, 70.07, 69.98, 69.24, 44.69, 36.15, 29.70, 21.67. mp (°C): 133-134.





The ee of **3ca'** was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 70:30, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{major} = 58.2$ min, $\tau_{minor} = 52.5$ min. HRMS ESI ORBITRAP (+) m/z: calculated for C₃₀H₂₈FeN₂O₇S 616.0967, found 639.0851 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 8.10 (d, J = 8.7 Hz, 2H), 7.84 – 7.76 (m, 2H), 7.38 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 8.7 Hz, 2H), 6.74 (d, J = 5.0 Hz, 1H), 4.82 (d, J = 31.8 Hz, 2H), 4.47 (d, J = 7.7 Hz, 2H), 4.31 (s, 5H), 4.10 – 4.02 (m, 1H), 3.77 – 3.66 (m, 1H), 2.54 (s, 3H), 2.47 (s, 3H), 2.34 (dd, J = 13.5, 6.5 Hz, 1H), 2.01 – 1.91 (m, 1H). ¹³C NMR (400 MHz, CDCl₃): 205.98, 170.40, 147.40, 145.07, 134.52, 130.31, 128.31, 127.49, 124.16, 84.59, 74.10, 72.01, 71.84, 70.50, 70.15, 69.94, 45.71, 40.76, 29.69, 25.34, 21.69. Mp (°C): 176-177.





(2S,4S,5R)-5-acetyl-4-(4-bromophenyl)-1-tosylpyrrolidin-2-ferrocenyl acetate (3da) and (2R,4S,5S)-5-acetyl-4-(4-bromophenyl)-1-tosylpyrrolidin-2-ferrocenyl acetate (3da')



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.04mmol., 13 mg, 10 mol%) was dissolved in 2.0 mL of CH₂Cl₂ and benzoic acid (0.08mmol., 10 mg, 20 mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar .The resulting solution was stirred at room temperature for 20 minutes, then 4-

bromocinnamicaldehyde (0.4mmol) and 4-methyl-N-(2-oxopropyl)benzene-sulfona mide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in *vacuo*. After flash column chromatography (hexane/ethyl acetate =4/1) reaction product was obtained as amorphous solid (158.0mg, 90% yield, dr=10:6, 3da 97% ee (Fc ester), 3da' 99% ee (FC ester)). The dr was determined by ¹H NMR and the ee of **3da** was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 70:30, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{major} = 10.2 \text{ min} \tau_{minor} =$ 35.1 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₃₀H₂₈BrFeNO₅S 649.0221, found 672.0110 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 7.82 (t, *J* = 7.5 Hz, 2H), 7.46 (t, J = 7.6 Hz, 2H), 7.34 (d, J = 7.2 Hz, 2H), 7.06 (t, J = 7.5 Hz, 2H), 6.78 (s, 1H),4.80 (d, J = 8.2 Hz, 2H), 4.61 (s, 1H), 4.41 (s, 2H), 4.23 (d, J = 7.2 Hz, 5H), 4.00 (d, J)= 7.8 Hz, 1H), 2.90 - 2.75 (m, 1H), 2.45 (d, J = 7.1 Hz, 3H), 2.23 - 2.11 (m, 1H), 1.65 (d, J = 7.2 Hz, 3H). ¹³C NMR (400 MHz, CDCl₃): 205.73, 170.73, 144.21, 136.48, 133.28, 132.11, 129.83, 129.63, 127.98, 122.26, 84.06, 71.55, 71.44, 70.34, 70.12, 70.07, 69.95, 69.38, 44.46, 36.13, 29.65, 21.65. Mp. (°C): 81-82.



Peak "	RetTime	Туре	Width	Area	Height	Area
#	[mīn]		[mīn]	[mAU^S]	[mau]	5
1	10.463	BB	0.5903	2.01965e4	501.05365	50.8543
2	35.307	MM T	2.7808	1.95180e4	116.98051	49.1457



The ee of **3da'** was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 70:30, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{major} = 18.1$ min, $\tau_{minor} = 34.0$ min. HRMS ESI ORBITRAP (+) m/z: calculated for C₃₀H₂₈BrFeNO₅S 649.0221, found 672.0110 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 7.80 (d, J = 8.2 Hz, 2H), 7.38 (dd, J = 8.1, 4.0 Hz, 4H), 6.87 (d, J = 8.4 Hz, 2H), 6.71 (d, J = 5.0 Hz, 1H), 4.83 (d, J = 26.0 Hz, 2H), 4.51 – 4.43 (m, 2H), 4.31 (s, 5H), 4.02 (d, J = 9.2 Hz, 1H), 3.57 (dd, J = 17.3, 10.4 Hz, 1H), 2.51 (s, 3H), 2.48 (s, 3H), 2.30 (dd, J = 13.5, 6.4 Hz, 1H), 1.99 – 1.87 (m, 1H). ¹³C NMR (400 MHz, CDCl₃): 206.00, 170.44, 144.85, 136.39, 134.66, 130.20, 128.93, 127.48, 121.79, 84.60, 74.35, 71.90, 71.75, 70.12, 69.96, 70.04, 45.67, 40.84, 29.70, 25.36, 21.69. Mp. (°C): 92-93.





(2S,4S,5R)-5-acetyl-4-(4-methoxyphenyl)-1-tosylpyrrolidin-2-ferrocenyl acetate (3fa) and (2R,4S,5S)-5-acetyl-4-(4-methoxyphenyl)-1-tosylpyrrolidin-2-ferrocenyl acetate (3fa')



Chiral amine catalyst 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.04mmol., 13 mg, 10 mol%) was dissolved in 2.0 mL of CH_2Cl_2 and benzoic acid (0.08mmol., 10 mg, 20 mol%) was added in an ordinary vial equipped with a Teflon-coated stir bar.

The resulting solution was stirred at room temperature for 20 minutes, then 4methoxyphenylacrylaldehyde (0.4mmol) and 4-methyl-N-(2-oxopropyl)benzene-sul fonamide (0.5mmol) was added. The vial was stirring continued at room temperature for 96 hours. The crude mixture was flushed through a short plug of silica. Solvent was removed in vacuo. After flash column chromatography (hexane/ethyl acetate =4/1) reaction product was obtained as amorphous solid (154.7mg, 99% yield, dr=10:6, 3fa >99% ee (Fc Ester), 3fa' 97% ee (Fc ester)). The dr was determined by ¹H NMR and the ee of **3fa** was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 70:30, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{maior} =$ 9.6 min, τ_{minor} = 30.4 min. HRMS ESI ORBITRAP (+) m/z: calculated for C₃₁H₃₁FeNO₆S 601.1222, found 624.1108 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 7.82 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 8.7 Hz, 2H), 6.84 (d, J= 8.7 Hz, 2H), 6.77 (d, J = 4.6 Hz, 1H), 4.78 (d, J = 8.8 Hz, 2H), 4.60 – 4.57 (m, 1H), 4.43 – 4.37 (m, 2H), 4.23 (s, 5H), 4.01 (dd, J = 11.1, 5.7 Hz, 1H), 3.78 (s, 3H), 2.82 (td, J = 13.5, 4.8 Hz, 1H), 2.44 (s, 3H), 2.15 (dd, J = 13.2, 5.8 Hz, 1H), 1.61 (s, 3H).¹³C NMR (400 MHz, CDCl₃): 206.09, 170.73, 159.36, 144.05, 136.70, 129.63, 129.20, 127.94, 114.31, 84.18, 71.51, 71.38, 70.39, 70.31, 70.10, 69.92, 69.66, 55.27, 44.35, 36.31, 29.53, 21.64. Mp. (°C): 173-174.





The ee of **3fc'** was determined by HPLC analysis on a Daicel Chiralpak AD-H column: hexane/*i*-PrOH 70:30, flow rate 0.80 mL/min, $\lambda = 254.0$ nm: $\tau_{major} = 9.6$ min, $\tau_{minor} = 35.5$ min. HRMS ESI ORBITRAP (+) m/z: calculated for C₃₁H₃₁FeNO₆S 601.1222, found 624.1108 [M+Na]⁺. ¹H NMR (400 MHz, CDCl₃): 7.82 (d, J = 8.2 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 6.93 (d, J = 8.6 Hz, 2H), 6.80 (d, J = 8.7 Hz, 2H), 6.69 (d, J = 5.0 Hz, 1H), 4.83 (d, J = 19.0 Hz, 2H), 4.46 (s, 2H), 4.31 (s, 5H), 4.01 (d, J = 9.6 Hz, 1H), 3.77 (s, 3H), 3.56 (ddd, J = 12.5, 9.8, 6.3 Hz, 1H), 2.47 (s, 3H), 2.46 (s, 3H), 2.28 (dd, J = 13.5, 6.3 Hz, 1H), 1.93 (td, J = 13.1, 5.1 Hz, 1H). ¹³C NMR (400 MHz, CDCl₃): 205.99 , 170.47 , 159.19 , 144.65 , 134.84 , 130.13 , 128.28 , 127.54 , 114.41 , 84.64 , 74.60 , 71.81, 71.68, 70.47, 70.09, 69.98, 55.28 , 45.74 , 41.25 , 29.70 , 25.30 , 21.66 . Mp. (°C): 218-219.



Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[mın]	[mAU*s]	[mAU]	8
		-				
1	9.627	MM T	0.5841	8464.16504	241.49837	49.7652
2	34.863	MM T	2.1203	8544.01953	67.16100	50.2348



NMR spectra



Compound 3aa ¹³C NMR



Compound **3aa'**¹³C NMR



Compound **3af**¹³C NMR



Compound **3bf** ¹³C NMR



Compound **3cf**¹³C NMR



Compound df ¹³C NMR



Compound **3ef** ¹³C NMR







Compound **3hf** ¹³C NMR



Compound **3if** ¹³C NMR



Compound **3ja**¹³C NMR





Compound 3je ¹³C NMR



Compound 3ca ¹³C NMR





Compound 3da ¹³C NMR







Compound 3fa ¹³C NMR